Moleculin approved reverse split authority for MBRX stock

Published on 10/14/2026 at 03:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moleculin authorized a 1-for-20 reverse split range on October 9, 2026. For MBRX stock this means 3,861,894 added plan shares.

Vote and clinical milestones

On October 9, 2026, shareholders authorized a reverse split ratio ranging from 1-for-2 to 1-for-20.
The amended stock plan added 3,861,894 authorized shares.
Moleculin Biotech will present its oncology program on October 14, 2026, with a Part A data readout planned for the first quarter of 2027.

MBRX, US60855D4088, Illustration mit AI erstellt.

Moleculin Biotech (ISIN US60855D4088) approved board authority for a reverse stock split on October 9, 2026, with a ratio ranging from 1-for-2 to 1-for-20. The vote also expanded the company's equity plan, putting capital structure and financing capacity at the center of the next investor discussion.

Shareholder vote changes capital tools

According to StockTitan, the October 9 annual meeting approved the reverse split authority before the meeting's one-year anniversary. The same filing reported 5,738,901 votes for, 2,488,513 against and 19,675 abstentions.

The amended 2024 Stock Plan increased the authorized share pool by 3,861,894 shares to 3,875,999. The filing also listed 19,477,380 common shares outstanding and entitled to vote as of August 19, 2026, making the potential equity expansion a material counter-factor for existing holders.

Clinical milestones set the timeline

In chronological order, GlobeNewswire reported a Mexican patent protecting lung-targeted liposomal Annamycin through November 23, 2040, on September 23, 2026. On September 29, 2026, the company reported 89 subjects enrolled in Part A of the MIRACLE trial, per GlobeNewswire.

The next dates are October 14, 2026, when CEO Walter Klemp is scheduled to present the oncology pipeline at the Maxim Growth Summit, and the first quarter of 2027 for the planned comprehensive Part A data readout, according to Moleculin.

What does the vote mean?

The authorization gives the board flexibility over a future 1-for-2 to 1-for-20 reverse split, but it does not itself execute a split. Moleculin's October 7 release also said the company will require significant additional financing for its clinical trials and had no commitments for that financing, leaving funding execution alongside trial data as a central risk.

Nasdaq context for MBRX

Moleculin Biotech was last at USD 0.44 on Nasdaq on October 13, 2026 at 4:00 p.m. ET. The market capitalization was USD 2.3 million as of October 13, 2026, while the biotechnology company continues developing Annamycin for relapsed or refractory acute myeloid leukemia and other hard-to-treat cancers.